NAMS: Obicetrapib advances toward launch with pivotal PREVAIL and RUBIN trial milestones ahead
Obicetrapib, a differentiated CETP inhibitor, is nearing key milestones with the PREVAIL cardiovascular outcomes trial and RUBIN diabetes study. The drug offers unique benefits over competitors, with interim PREVAIL results expected in Q1 next year and a potential launch within 12—18 months.Based o…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.